small molecule

EPINEPHRINE

EPINEPHRINE

Loss of exclusivityJanuary 2045latest FDA-listed patent expiry
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameEPINEPHRINE
Active ingredientEPINEPHRINE
Strength30MG/30ML (1MG/ML)
Dosage formSOLUTION
RouteINTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
ModalitySmall molecule
FDA approvalMarch 2025
Marketing statusRX

Listed patents

PatentExpiresType
12539283January 2045product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.